Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADVIL ALLERGY AND CONGESTION RELIEF vs HYDROCODONE BITARTRATE AND IBUPROFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction.
Hydrocodone is a semisynthetic opioid agonist with selectivity for mu-opioid receptors, producing analgesia and sedation. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby providing anti-inflammatory, analgesic, and antipyretic effects.
Temporary relief of symptoms due to hay fever or other upper respiratory allergies: nasal congestion, sinus pressure, sneezing, runny nose, itching of nose or throat, and itchy, watery eyes due to allergies.,Temporary reduction of fever.,Relief of minor aches and pains associated with the common cold, headache, toothache, muscular aches, backache, menstrual cramps, and arthritis pain.
Short-term (up to 10 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Ibuprofen 200 mg and pseudoephedrine HCl 30 mg per tablet. Usual adult dose: 1-2 tablets orally every 4-6 hours as needed, not to exceed 6 tablets in 24 hours.
One tablet (hydrocodone bitartrate 5 mg/ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
Ibuprofen: 2-4 hours; pseudoephedrine: 5-8 hours. Shorter half-life requires frequent dosing for sustained relief.
Hydrocodone: 3.8-4.5 hours (immediate release); Ibuprofen: 1.8-2.5 hours (racemic, S-enantiomer slightly shorter). Clinical context: dosing every 4-6 hours due to hydrocodone half-life.
Ibuprofen is primarily metabolized by cytochrome P450 (CYP) enzymes, mainly CYP2C9, to inactive metabolites (hydroxyibuprofen and carboxyibuprofen). Pseudoephedrine is partially metabolized in the liver by N-demethylation to an inactive metabolite.
Hydrocodone is primarily metabolized by CYP3A4 and CYP2D6 enzymes to hydromorphone (active) and norhydrocodone (inactive). Ibuprofen is metabolized by CYP2C9 to inactive metabolites (hydroxyibuprofen and carboxyibuprofen).
Renal excretion of unchanged drug and metabolites; approximately 1% excreted unchanged (pseudoephedrine) and 15% (ibuprofen). Biliary/fecal elimination accounts for <5%.
Hydrocodone: primarily renal (60-70% as metabolites, <12% unchanged); Ibuprofen: primarily renal (90% as metabolites and conjugates, <1% unchanged), minor biliary/fecal.
Ibuprofen: 99% bound to albumin; pseudoephedrine: negligible protein binding.
Hydrocodone: ~19% bound to plasma proteins; Ibuprofen: >99% bound to albumin.
Ibuprofen: 0.1-0.2 L/kg; pseudoephedrine: 2.5-3 L/kg.
Hydrocodone: 3.3-4.7 L/kg; Ibuprofen: 0.1-0.2 L/kg. High Vd for hydrocodone indicates extensive tissue distribution; low Vd for ibuprofen indicates plasma and interstitial fluid confinement.
Oral: ibuprofen 80-100%; pseudoephedrine 100%.
Hydrocodone: mean absolute bioavailability ~70-80% (oral); Ibuprofen: ~80-100% (oral, rapid absorption).
For pseudoephedrine: Cr Cl <30 m L/min, reduce dose by 50% or administer every 12 hours. For ibuprofen: avoid use if Cr Cl <30 m L/min; if Cr Cl 30-59 m L/min, use lowest effective dose and monitor renal function.
GFR 30-60 m L/min: Use with caution, consider reducing dose or increasing interval. GFR <30 m L/min: Not recommended due to accumulation of ibuprofen and hydrocodone metabolites.
For ibuprofen: Child-Pugh class A and B: no adjustment necessary; Child-Pugh class C: avoid use. For pseudoephedrine: use with caution in severe hepatic impairment; no specific dose adjustment recommended, but monitor for adverse effects.
Child-Pugh Class B: Start with lowest possible dose, monitor closely. Child-Pugh Class C: Contraindicated due to risk of toxicity.
Not indicated for children under 12 years of age. For children 12 years and older: same as adult dose (1-2 tablets every 4-6 hours, max 6 tablets per day). Weight-based: not routinely used; safety and efficacy not established for <25 kg.
Not recommended for use in pediatric patients; safety and efficacy not established.
For ibuprofen: use lowest effective dose for shortest duration; monitor renal function and GI bleeding risk. For pseudoephedrine: initiate at lower doses (e.g., one tablet every 6 hours) due to increased sensitivity and risk of hypertension, urinary retention, and CNS effects.
Initiate with lowest effective dose (e.g., half tablet) and monitor for CNS and respiratory depression; reduce maximum daily dose to 4 tablets due to increased sensitivity and renal impairment.
Cardiovascular risk: NSAIDs may increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. Contraindicated for perioperative pain in coronary artery bypass graft (CABG) surgery. Gastrointestinal risk: NSAIDs increase the risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients and those with prior peptic ulcer disease and/or GI bleeding are at greater risk.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from ibuprofen (NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation, which can be fatal).
Cardiovascular effects: may increase risk of heart attack or stroke; use lowest effective dose for shortest duration. Gastrointestinal effects: may cause GI ulceration, bleeding, perforation. Renal effects: avoid in advanced renal disease; monitor renal function. Hepatic effects: may cause liver enzyme elevation; discontinue if liver disease develops. Anaphylactic reactions: may occur in patients with or without prior NSAID sensitivity. Asthma: may cause bronchospasm. Hypertension: may worsen hypertension. Avoid in late pregnancy due to risk of premature closure of ductus arteriosus. Pseudoephedrine: may cause nervousness, dizziness, insomnia, hypertension, arrhythmias; use with caution in patients with cardiovascular disease, diabetes, glaucoma, prostatic hypertrophy, hyperthyroidism. Avoid in severe hypertension or coronary artery disease.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with CNS depressants; severe hypotension; adrenal insufficiency; hepatotoxicity; gastrointestinal bleeding, ulceration, and perforation; cardiovascular thrombotic events; hypertension; renal toxicity; anaphylactoid reactions; serious skin reactions; use in pregnancy; use in breastfeeding; use in hepatic impairment; use in renal impairment; use in elderly; use in patients with bleeding disorders.
Hypersensitivity to ibuprofen, pseudoephedrine, or any component of the formulation. History of asthma, urticaria, or allergic-type reaction after taking aspirin or other NSAIDs. In the setting of coronary artery bypass graft (CABG) surgery. Severe hypertension. Coronary artery disease. Concurrent use with or within 14 days of monoamine oxidase inhibitors (MAOIs) due to risk of hypertensive crisis. Pregnancy (third trimester).
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction; hypersensitivity to hydrocodone, ibuprofen, or any component; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain relief in the setting of coronary artery bypass graft (CABG) surgery; use within 14 days of monoamine oxidase inhibitor (MAOI) therapy.
Take with food or milk to minimize GI upset. Avoid alcohol as it may increase risk of GI bleeding. No specific food-drug interactions.
Grapefruit and grapefruit juice may increase hydrocodone levels and risk of adverse effects; avoid concurrent use. Alcohol potentiates CNS depression and increases GI bleeding risk; avoid altogether. High-fat meals may delay absorption of hydrocodone, but clinical impact is minimal; take consistently with or without food.
First trimester: Possible increased risk of cardiovascular malformations and gastroschisis with NSAID use. Second trimester: No specific malformation risk reported, but avoid prolonged use due to potential oligohydramnios. Third trimester: NSAIDs (including ibuprofen) are contraindicated due to risk of premature ductus arteriosus closure and oligohydramnios. Pseudoephedrine: Limited data; possible association with gastroschisis if used in first trimester; avoid due to vasoconstrictive effects.
Pregnancy Category C: No adequate studies in pregnant women. Ibuprofen (NSAID) is associated with increased risk of premature closure of ductus arteriosus and oligohydramnios in third trimester; avoid after 30 weeks gestation. Hydrocodone may cause respiratory depression in neonate if used near term; chronic use may lead to neonatal opioid withdrawal syndrome. First trimester: limited data, but NSAIDs may increase risk of miscarriage; hydrocodone not associated with major malformations. Second trimester: generally considered safer, but risks remain. Third trimester: avoid NSAIDs; hydrocodone use only if benefit outweighs risk.
Ibuprofen: Excreted in low levels (M/P ratio ~0.006); considered compatible with breastfeeding. Pseudoephedrine: Excreted in breast milk (M/P ratio ~2.5-3.5); may reduce milk production and cause irritability in infants; use with caution.
Limited data; both drugs excreted into breast milk. Ibuprofen M/P ratio ~0.01, considered compatible. Hydrocodone M/P ratio ~2.0; low levels in milk but risk of infant sedation and respiratory depression. Use caution; monitor infant for drowsiness, difficulty breastfeeding. American Academy of Pediatrics considers hydrocodone as 'usually compatible' but avoid when possible. Alternatives preferred.
Ibuprofen: No specific dose adjustment recommended for pregnancy; however, avoid use in third trimester. Pseudoephedrine: No dose adjustment studied; use lowest effective dose for shortest duration. Neither drug is recommended for regular use during pregnancy.
No specific pharmacokinetic studies; however, pregnancy increases clearance and volume of distribution for both drugs. Ibuprofen: dose adjustments not typically recommended, but due to renal effects and fetal risks, use lowest effective dose for shortest duration. Hydrocodone: increased clearance may require higher doses to achieve analgesic effect; consider patient-specific titration. However, due to neonatal risks, minimize use and duration.
Combination of ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen may increase blood pressure, counteracting pseudoephedrine's vasoconstriction; monitor in hypertensive patients. Avoid in patients with severe CAD, uncontrolled HTN, or within 2 weeks of MAOI use.
Hydrocodone/ibuprofen combines an opioid agonist with an NSAID. Be aware of additive risks: respiratory depression, sedation, GI bleeding, renal impairment, and cardiovascular thrombotic events. Avoid in patients with severe asthma, GI obstruction, or after recent bariatric surgery. Use lowest effective dose for shortest duration. Monitor for serotonin syndrome if used with other serotonergic drugs. Abrupt discontinuation after prolonged use may cause withdrawal.
Do not take with other NSAIDs or cold/flu products to avoid overdose.,Pseudoephedrine may cause insomnia; take last dose at least 4-6 hours before bedtime.,Ibuprofen can cause GI bleeding; take with food or milk to reduce risk.,Stop use and consult doctor if symptoms persist >7 days or if fever lasts >3 days.,Avoid alcohol while taking this medication.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Hydrocodone can cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants (e.g., benzodiazepines, other opioids) while taking this medication.,Ibuprofen may increase risk of stomach bleeding; report black/tarry stools, coffee-ground vomit, or abdominal pain.,Avoid other NSAIDs (e.g., aspirin, naproxen) or COX-2 inhibitors to prevent additive GI and renal toxicity.,Store securely away from children and others; dispose of unused medication via take-back programs.,Do not abruptly stop after long-term use; withdrawal symptoms may occur (anxiety, sweating, nausea).
No interactions on record
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADVIL ALLERGY AND CONGESTION RELIEF vs HYDROCODONE BITARTRATE AND IBUPROFEN, answered by our medical review team.
ADVIL ALLERGY AND CONGESTION RELIEF is a NSAID/Decongestant Combination that works by Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction.. HYDROCODONE BITARTRATE AND IBUPROFEN is a NSAID that works by Hydrocodone is a semisynthetic opioid agonist with selectivity for mu-opioid receptors, producing analgesia and sedation. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby providing anti-inflammatory, analgesic, and antipyretic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADVIL ALLERGY AND CONGESTION RELIEF and HYDROCODONE BITARTRATE AND IBUPROFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADVIL ALLERGY AND CONGESTION RELIEF is: Ibuprofen 200 mg and pseudoephedrine HCl 30 mg per tablet. Usual adult dose: 1-2 tablets orally every 4-6 hours as needed, not to exceed 6 tablets in 24 hours.. The standard adult dose of HYDROCODONE BITARTRATE AND IBUPROFEN is: One tablet (hydrocodone bitartrate 5 mg/ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADVIL ALLERGY AND CONGESTION RELIEF and HYDROCODONE BITARTRATE AND IBUPROFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADVIL ALLERGY AND CONGESTION RELIEF is classified as Category C. First trimester: Possible increased risk of cardiovascular malformations and gastroschisis with NSAID use. Second trimester: No specific malformation risk reported, but avoid prolo. HYDROCODONE BITARTRATE AND IBUPROFEN is classified as Category D/X. Pregnancy Category C: No adequate studies in pregnant women. Ibuprofen (NSAID) is associated with increased risk of premature closure of ductus arteriosus and oligohydramnios in th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.